Upadacitinib

Trade Name: 
Rinvoq
Manufacturer/Distributor: 
AbbVie Corporation
Classification: 
Disease-modifying antirheumatic agent
ATC Class: 
L04AA44 - upadacitinib
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2019/12/23
Date Marketed in Canada (yyyy/mm/dd): 
2020/01/16
Presentation: 
Tablet: 15 mg. DIN: 02495155
Comments: 
Extended release tablet for treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to methotrexate. May also be used in combination with methotrexate or other non-biologic DMARDs.